Format

Send to

Choose Destination
Mol Cancer. 2017 Dec 6;16(1):177. doi: 10.1186/s12943-017-0745-1.

Generation of stable PDX derived cell lines using conditional reprogramming.

Author information

1
Bioscience, Oncology, IMED Biotech Unit, AstraZeneca, Boston, USA.
2
Propagenix Inc, 9605 Medical Center Drive #325, Rockville, MD, 20850, USA.
3
Bioscience, Oncology, IMED Biotech Unit, AstraZeneca, Boston, USA. Celina.DCruz@astrazeneca.com.

Abstract

Efforts to develop effective cancer therapeutics have been hindered by a lack of clinically predictive preclinical models which recapitulate this complex disease. Patient derived xenograft (PDX) models have emerged as valuable tools for translational research but have several practical limitations including lack of sustained growth in vitro. In this study, we utilized Conditional Reprogramming (CR) cell technology- a novel cell culture system facilitating the generation of stable cultures from patient biopsies- to establish PDX-derived cell lines which maintain the characteristics of the parental PDX tumor. Human lung and ovarian PDX tumors were successfully propagated using CR technology to create stable explant cell lines (CR-PDX). These CR-PDX cell lines maintained parental driver mutations and allele frequency without clonal drift. Purified CR-PDX cell lines were amenable to high throughput chemosensitivity screening and in vitro genetic knockdown studies. Additionally, re-implanted CR-PDX cells proliferated to form tumors that retained the growth kinetics, histology, and drug responses of the parental PDX tumor. CR technology can be used to generate and expand stable cell lines from PDX tumors without compromising fundamental biological properties of the model. It offers the ability to expand PDX cells in vitro for subsequent 2D screening assays as well as for use in vivo to reduce variability, animal usage and study costs. The methods and data detailed here provide a platform to generate physiologically relevant and predictive preclinical models to enhance drug discovery efforts.

KEYWORDS:

Cell line models; Conditional reprogramming; Drug discovery; Oncology; Patient derived xenograft

PMID:
29212548
PMCID:
PMC5719579
DOI:
10.1186/s12943-017-0745-1
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center